Ezra Cohen, MD

Ezra Cohen, MD, discusses the advancing field of immunotherapy in the treatment landscape for patients with head and neck cancers. Prior to the use of PD-1/PD-L1 blockades, which have been the most tested immunotherapy in this setting, there were little treatment options.

Cohen says while the data from the study looking at nivolumab has not been released yet, the halting of the trial due it having met its primary OS endpoint likely means good news.

The two platforms involved in the study were the FHX regimen and a cisplatin radiation approach with accelerated radiation. Siltuximab was also used in the study as induction chemotherapy alongside carboplatin and paclitaxel.

Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses immunotherapy in head and neck cancer.

Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses new data on immunotherapies for head and neck cancers.